Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Cash & Equivalents (2020 - 2025)

Bioventus (BVS) has disclosed Cash & Equivalents for 6 consecutive years, with $51.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 23.22% year-over-year to $51.2 million, compared with a TTM value of $51.2 million through Dec 2025, up 23.22%, and an annual FY2025 reading of $51.2 million, up 23.22% over the prior year.
  • Cash & Equivalents was $51.2 million for Q4 2025 at Bioventus, up from $42.2 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $138.1 million in Q3 2021 and bottomed at $22.8 million in Q1 2025.
  • Average Cash & Equivalents over 5 years is $53.2 million, with a median of $41.6 million recorded in 2024.
  • Peak annual rise in Cash & Equivalents hit 80.63% in 2021, while the deepest fall reached 49.41% in 2021.
  • Year by year, Cash & Equivalents stood at $43.9 million in 2021, then crashed by 31.29% to $30.2 million in 2022, then increased by 22.45% to $37.0 million in 2023, then grew by 12.49% to $41.6 million in 2024, then increased by 23.22% to $51.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for BVS at $51.2 million in Q4 2025, $42.2 million in Q3 2025, and $32.9 million in Q2 2025.